Prelude Capital Management’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-23,160
| Closed | -$301K | – | 1139 |
|
|
2025
Q2 | $301K | Buy |
+23,160
| New | +$274K | 0.03% | 611 |
|
|
2024
Q4 | – | Sell |
-12,519
| Closed | -$291K | – | 1207 |
|
|
2024
Q3 | $291K | Buy |
12,519
+533
| +4% | +$11.4K | 0.02% | 884 |
|
|
2024
Q2 | $292K | Buy |
+11,986
| New | +$363K | 0.02% | 805 |
|
|
2024
Q1 | – | Sell |
-9,359
| Closed | -$295K | – | 1303 |
|
|
2023
Q4 | $295K | Buy |
9,359
+897
| +11% | +$21.3K | 0.02% | 744 |
|
|
2023
Q3 | $216K | Sell |
8,462
-364
| -4% | -$11.2K | 0.01% | 855 |
|
|
2023
Q2 | $253K | Sell |
8,826
-3,768
| -30% | -$103K | 0.02% | 724 |
|
|
2023
Q1 | $302K | Buy |
+12,594
| New | +$226K | 0.02% | 640 |
|
|
2022
Q3 | – | Sell |
-11,753
| Closed | -$185K | – | 1567 |
|
|
2022
Q2 | $185K | Buy |
+11,753
| New | +$231K | 0.01% | 1308 |
|
|
2020
Q4 | – | Sell |
-5,727
| Closed | -$388K | – | 1282 |
|
|
2020
Q3 | $246K | Sell |
5,727
-2,073
| -27% | -$103K | 0.01% | 622 |
|
|
2020
Q2 | $365K | Sell |
7,800
-23,539
| -75% | -$811K | 0.02% | 564 |
|
|
2020
Q1 | $426K | Buy |
31,339
+478
| +2% | +$6.12K | 0.03% | 339 |
|
|
2019
Q4 | $335K | Buy |
30,861
+8,231
| +36% | +$86.2K | 0.01% | 682 |
|
|
2019
Q3 | $232K | Buy |
22,630
+5,113
| +29% | +$55.3K | 0.01% | 723 |
|
|
2019
Q2 | $165K | Sell |
17,517
-7,272
| -29% | -$53.4K | 0.01% | 796 |
|
|
2019
Q1 | $169K | Buy |
+24,789
| New | +$127K | 0.01% | 771 |
|
|
2018
Q3 | – | Sell |
-1,100
| Closed | -$9K | – | 1714 |
|
|
2018
Q2 | $9K | Buy |
+1,100
| New | +$7.12K | ﹤0.01% | 1498 |
|
|
2017
Q4 | – | Sell |
-1,171
| Closed | -$8K | – | 1347 |
|
|
2017
Q3 | $8K | Buy |
1,171
+1,157
| +8,264% | +$8.72K | ﹤0.01% | 1451 |
|
|
2017
Q2 | $0 | Buy |
+14
| New | +$113 | ﹤0.01% | 1590 |
|
|
2016
Q3 | – | Sell |
-29
| Closed | -$1K | – | 1578 |
|
|
2016
Q2 | $1K | Buy |
+29
| New | +$914 | ﹤0.01% | 1527 |
|
|
2014
Q4 | – | Sell |
-29
| Closed | -$3K | – | 1883 |
|
|
2014
Q3 | $3K | Sell |
29
-357
| -92% | -$46.5K | ﹤0.01% | 1820 |
|
|
2014
Q2 | $47K | Sell |
386
-785
| -67% | -$94.8K | 0.01% | 1375 |
|
|
2014
Q1 | $149K | Buy |
+1,171
| New | +$174K | 0.02% | 841 |
|
|
2013
Q4 | – | Sell |
-200
| Closed | -$25K | – | 1609 |
|
|
2013
Q3 | $25K | Buy |
+200
| New | +$17.8K | ﹤0.01% | 1202 |
|
Other funds holding ARCT
NAMA
AIM
SSA
Prelude Capital Management's ARCT Position: Q3 2025 in Review
Prelude Capital Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 23,160 shares — an estimated $301K sold.
Prelude Capital Management first reported a position in ARCT in Q3 2013 and held it in 23 quarters. The position peaked at $426K in Q1 2020. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.
- Prelude Capital Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
- Prelude Capital Management sold 23,160 Arcturus Therapeutics shares in Q3 2025, an estimated $301K.
- Prelude Capital Management first reported a position in Arcturus Therapeutics in Q3 2013 and held it in 23 quarters.
- Prelude Capital Management's Arcturus Therapeutics position peaked at $426K in Q1 2020.
- 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.
Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.